Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.03
$0.65
$0.03
$0.59
$857K0.226.48 million shsN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.66
$13.23
$8.95
$19.11
$1.15B1.721.21 million shs3.55 million shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$6.06
+0.2%
$6.12
$3.75
$9.40
$27.31M1.5321,375 shs7,919 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.65
$1.44
$1.09
$2.73
$512.49M2.356.21 million shs19.17 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00%0.00%0.00%0.00%-16.05%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+0.59%+0.59%+15.27%+41.70%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.00%+3.15%+2.98%+29.94%+31.63%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
0.00%+17.86%+10.74%+30.95%+27.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.03
$0.65
$0.03
$0.59
$857K0.226.48 million shsN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.66
$13.23
$8.95
$19.11
$1.15B1.721.21 million shs3.55 million shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$6.06
+0.2%
$6.12
$3.75
$9.40
$27.31M1.5321,375 shs7,919 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.65
$1.44
$1.09
$2.73
$512.49M2.356.21 million shs19.17 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00%0.00%0.00%0.00%-16.05%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+0.59%+0.59%+15.27%+41.70%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.00%+3.15%+2.98%+29.94%+31.63%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
0.00%+17.86%+10.74%+30.95%+27.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00
N/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$37.83176.96% Upside
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.00
Hold$6.00-0.91% Downside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.80
Reduce$1.8311.11% Upside

Current Analyst Ratings Breakdown

Latest PACB, AXDX, HBIO, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Reiterated RatingSell (D-)
6/24/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingBuy$68.00
5/11/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Boost Price TargetUnderweight$1.00 ➝ $1.50
5/7/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Lower Price TargetOutperform$39.00 ➝ $37.00
4/21/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingSell (D-)
4/21/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Reiterated RatingSell (E+)
4/20/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
DowngradeStrong-BuyHold
4/14/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Lower Price TargetUnderweight$1.50 ➝ $1.00
(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$11.70M0.07N/AN/A($1.37) per share-0.02
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$31.37M36.51N/AN/A$3.70 per share3.69
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$86.55M0.32$11.64 per share0.52$3.07 per share1.97
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$160.01M3.20$0.79 per share2.09$0.02 per share82.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$2.34N/AN/AN/A-471.83%N/A-191.66%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$231.96M-$3.50N/AN/AN/A-3,566.63%-110.54%-90.15%8/5/2026 (Estimated)
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$56.70M-$2.17N/AN/AN/A-11.44%-25.78%-4.37%8/10/2026 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$546.38M-$0.43N/AN/AN/A-80.35%-571.06%-18.82%8/3/2026 (Estimated)

Latest PACB, AXDX, HBIO, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$0.62-$0.33+$0.29-$0.77$21.20 million$20.76 million
5/7/2026Q1 2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.17-$0.12+$0.05-$0.03$39.94 million$37.18 million
5/6/2026Q1 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
1.50
1.34
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
6.66
6.63
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.60
1.99
1.06
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
5.65
4.87
CompanyEmployeesShares OutstandingFree FloatOptionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
22025.21 million14.13 millionNo Data
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12083.84 million79.54 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4904.51 million3.59 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730310.60 million299.11 millionOptionable

Recent News About These Companies

Pacific Biosciences: Pressure Is Rising
Pacific Biosciences (PACB) Reports Q1 EPS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Accelerate Diagnostics stock logo

Accelerate Diagnostics NASDAQ:AXDX

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$13.66 0.00 (0.00%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$13.84 +0.18 (+1.28%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$6.06 +0.02 (+0.25%)
Closing price 06/26/2026 03:59 PM Eastern
Extended Trading
$5.67 -0.38 (-6.34%)
As of 07:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.65 0.00 (0.00%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$1.65 0.00 (0.00%)
As of 08:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.